<DOC>
	<DOCNO>NCT02907619</DOCNO>
	<brief_summary>This study open-label extension protocol B5161002 provide assessment long term safety , efficacy , pharmacodynamics pharmacokinetics intravenous dose PF 06252616 boy Duchenne muscular dystrophy . Approximately 105 eligible subject assign receive monthly individualize maximum tolerate dose base tolerability profile/data B5161002 . This study contain placebo comparator . Subjects undergo safety evaluation ( Laboratory , cardiac monitoring , physical exam , x-ray , MRI ) , functional capacity evaluation ( 4 stair climb , range motion , strength testing , Northstar Ambulatory Assessment , upper limb functional testing , six minute walk test pulmonary function test ) pharmacokinetic testing .</brief_summary>
	<brief_title>An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Subjects Duchenne muscular dystrophy enrol complete study B5161002 . 2 . Signed date informed consent document ( ICD ) indicate subject 's parent legal guardian/caregiver inform pertinent aspect study . 3 . Subjects legal guardians/caregivers willing able comply schedule visit , treatment plan , laboratory test , study procedure . 4 . Subject ; 1 . Adequate hepatic function screen laboratory assessment 2 . GLDH le 20 units/liter ( 2 x upper limit normal [ ULN ] ) 3 . Iron content estimate liver MRI within normal range . 1 . Unwilling unable ( eg , metal implant ) undergo examination close MRI . 2 . All male subject able father child sexually active risk impregnate female partner , unwilling unable use highly effective method contraception . In addition , sexually active male subject unwilling unable prevent potential transfer exposure drug semen partner use condom consistently correctly . . 3 . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised Investigator , subject related Pfizer employee directly involve conduct study . 4 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation . 5 . Participation study involve investigational drug ( ) , exception B5161002 . 6 . History allergic anaphylactic reaction therapeutic diagnostic protein additives investigational product .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Duchenne muscular dystrophy , myostatin , open-label</keyword>
</DOC>